Chronic inflammatory demyelinating polyneuropathy
Autonomic Dysfunction in Iraqi Patients with Chronic Inflammatory Demyelinating Polyneuropathy
... Abstract: Objective:The purpose of this study is to evaluate the autonomic disturbance in patients with chronic inflammatory demyelinating polyneuropathy.Methods:Thirty-eight patients who fit into ...
9
Quantitative grip force assessment of muscular weakness in chronic inflammatory demyelinating polyneuropathy
... from Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) disease severity is assessed by Medical Research Counsil (MRC) Scale or Inflammatory Neuropathy Cause and Treatment (INCAT) ...
9
Diagnostics of Sensory Ataxia in Patients with Sensory Predominant Chronic Inflammatory Demyelinating Polyneuropathy from Republic of Sakha (Yakutia) and Krasnoyarsk Region
... activity chronic peripheral polyneuropathies, including sensory predominant chronic inflammatory demyelinating polyneuropathy ...[6]. Polyneuropathy with the affection of ...
10
Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins
... Abstract: Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired hetero- geneous disorder of immune origin affecting the peripheral nerves, causing motor weakness and sensory ...
5
Pathway construction of chronic inflammatory demyelinating polyneuropathy (CIPD): a neurodegenerative disease
... Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an auto immune disorder which affects the peripheral nervous system of Human body (Peripher, ...is chronic form of ...
7
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial
... CIDP, chronic inflammatory demyelinating polyneuropathy; EFNS/PNS, European Federation of Neurological Societies/ Peripheral Nerve Society; EQ-5D, EuroQoL 5-Dimension Questionnaire; HRQL, ...
15
Sural nerve T-cell receptor V gene utilization in chronic inflammatory demyelinating polyneuropathy and vasculitic neuropathy
... with chronic inflammatory demyelinating polyneuropathy (CIDP) and vasculitic neuropa- ...with chronic idiopathic axonal polyneuropathy (CIAP) who acted as noninflammatory ...
10
A Case of Acquired Chronic Inflammatory Demyelinating Polyneuropathy
... of chronic acquired demyelinating polyneuropathy (CADP), is a rare autoimmune demyelinating disorder characterized by muscle weakness and fasciculation more commonly in upper ...from ...
8
Chronic inflammatory demyelinating polyneuropathy-like neuropathy as an initial presentation of Crohn’s disease
... of chronic inflammatory demyelinating polyneuropathy (CIDP) have been reported [7-11], but in those cases the patients developed their symptoms after CD had been established during various ...
5
Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy
... Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated neuropathy worldwide, with an estimated prevalence of 2–7 per 100,000 people ...
8
Autonomic dysfunction in chronic inflammatory demyelinating polyneuropathy.
... Chronic inflammatory demyelinating polyneuropathy (CIDP) is a common cause of autoimmune neuropathy, described first in 1958 by James Austin as steroid-responsive relapsing ...
92
Loss of Schwann cell plasticity in chronic inflammatory demyelinating polyneuropathy (CIDP)
... in order to prevent its regeneration for 120 days (±2 days). Within the period of 120 days of chronic denervation, Schwann cells were cultured from neonatal rats. Lack of re- generation was confirmed by absence of ...
9
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial
... the Inflammatory Neuropathy Consortium (INC), a standing committee of the Peripheral Nerve Society, and is a member of the Scientific Board of the Kreuth III meeting on the optimal use of plasma-derived medicinal ...
39
Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada
... The model was also evaluated using dif- ferent assumptions about the utility gain from IVIG, the extrapolation of IVIG relapse rates, treatment switching for corticosteroid patients afte[r] ...
9
<p>Two comparative assessments of intravenous immunoglobulin therapy switching patterns in the treatment of chronic inflammatory demyelinating polyneuropathy in the US</p>
... Study 1 required patients to receive IVIG as their fi rst treatment after diagnosis of CIDP, excluding patients who received all other CIDP-related therapies as their initial treatment. I[r] ...
7
A continuous repetitive task to detect fatigability in spinal muscular atrophy
... CIDP: Chronic inflammatory demyelinating polyneuropathy; HMSN: Hereditary motor and sensory neuropathy; ICC: Intra- class correlation coefficients; LGMD: Limb girdle muscular dystrophy; LMM: ...
7
Nerve ultrasound characterizes AMN polyneuropathy as inhomogeneous and focal hypertrophic
... and demyelinating polyneuropathy is seen (Class 1 according to [11]), with a cross-sectional area (CSA) of 44 mm 2 in the UA (Ia) and 11mm 2 in the FA – ...a chronic inflammatory ...
7
A REVIEW ON PATHOGENESIS AND TREATMENT OF DIABETIC NEUROPATHY
... mimic chronic inflammatory demyelinating polyneuropathy, alcoholic neuropathy, and other endocrine neuropathies, hence, before labelling diabetic neuropathy it is mandatory to exclude all ...
13
Deciphering immune mechanisms in chronic inflammatory demyelinating polyneuropathies
... Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease of the periph- eral nerves and nerve ...common chronic autoimmune neuropathy in humans and is estimated ...
13
Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab
... abnormalities in the lower extremities including absent sensory response in the right sural nerve, markedly slowed conduction velocities between the ankle and below the fibular head stimulation, severely reduced compound ...
5